Search results
Results from the WOW.Com Content Network
An antihemorrhagic (British English: antihaemorrhagic) agent is a substance that promotes hemostasis (a process which stops bleeding). [1] It may also be known as a hemostatic (also spelled haemostatic) agent.
An anticoagulant, commonly known as a blood thinner, is a chemical substance that prevents or reduces the coagulation of blood, prolonging the clotting time. [1] Some occur naturally in blood-eating animals, such as leeches and mosquitoes, which help keep the bite area unclotted long enough for the animal to obtain blood.
An antithrombotic agent is a drug that reduces the formation of blood clots (). [1] [2] Antithrombotics can be used therapeutically for prevention (primary prevention, secondary prevention) or treatment of a dangerous blood clot (acute thrombus).
human anti-chimeric antibody: HACE: High-altitude cerebral edema: HACEK: acronym for a group of bacteria that are a frequent cause of endocarditis in children HAD: HIV-associated dementia: HADS: Hospital Anxiety and Depression Scale: HAE: hereditary angioedema: H/A: headache: HAI: healthcare-associated infection or hospital-acquired infection: HALE
Generally, drugs outlined within the ATC code B02 should be included in this category. Please see WP:PHARM:CAT for more information. The main article for this category is Antihemorrhagic .
Warfarin is indicated for the prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism; [9] prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement; [9] and reduction in the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after ...
Thrombin demonstrates a high level of allosteric regulation. [2] Allosterism in thrombin is regulated by the exosites 1 and 2 and the sodium binding site. A recent patent review has shown that the general consensus among researchers is that allosteric inhibitors may provide a more regulatable anticoagulant. [3]
Two non-hemorrhagic side effects of heparin treatment are known. The first is an elevation of serum aminotransferase levels, which has been reported in as many as 80% of patients receiving heparin. This abnormality is not associated with liver dysfunction, and it disappears after the drug is discontinued.